Nadofaragene firadenovec, PD-1 inhibitors show synergistic activity in bladder cancer
May 18th 2022“These findings are hypothesis-generating and suggest a possible therapeutically synergistic role for immune checkpoint blockade in [patients with] BCG-unresponsive NMIBC who may have partial or short-term response to nadofaragene treatment,” said lead study author Anirban P. Mitra, MD, PhD.
Antegrade instillation of mitomycin gel is effective in patients with UTUC
May 17th 2022“[Mitomycin gel] is efficacious as a [chemoablation] agent in adult patients with low-grade upper tract urothelial cancer, and while it’s FDA approved for both antegrade and retrograde administration, prior reports are limited to the retrograde experience,” said study investigator Kyle Rose, MD.
Dr. Murray on real-world study of antegrade administration of reverse thermal mitomycin gel for UTUC
May 16th 2022Katie Murray, DO, discusses findings from a real-world study of antegrade administration of reverse thermal mitomycin gel for primary chemoablation of upper tract urothelial carcinoma via percutaneous nephrostomy tube.
Low-power thulium laser enucleation of the prostate found efficacious in prostates larger than 80 mL
May 15th 2022“Our results showed significant improvement in postoperative urgency and UUI (P = .005) with no significant change in IIEF-5 score at 6-month follow-up compared to baseline,” wrote the authors.
Conservative management feasible for uncomplicated renal colic patients with positive urine cultures
May 15th 2022“Though septic stones are well recognized as a medical emergency, patients with uncomplicated renal colic (without systemic inflammatory responses or renal impairment) and positive urine cultures pose a dilemma in management considerations,” the investigators explained in their abstract.
HoLEP improves outcomes in patients with LUTS related to benign prostatic enlargement
May 15th 2022“HoLEP had a greater uroflowmetry improvement compared to open adenomectomy and TURP,” the investigators concluded. “The mean hospital stay and postoperative catheterization days were reduced compared to open adenomectomy, but there were no differences in this aspect with TURP.”
Adjuvant nivolumab benefit in urothelial carcinoma sustained with longer follow-up
May 14th 2022Adjuvant nivolumab continued to demonstrate a clinically meaningful disease-free survival benefit in patients with high-risk, muscle-invasive urothelial carcinoma, according to extended follow-up from the phase 3 CheckMate 274 trial.
Rezum reduces lower urinary tract symptoms in men with BPH
November 4th 2021"If you look at men who had sexual dysfunction at the beginning of the study, compared to men that had good sexual function at the beginning of a study, both groups of men have equal response to improvement in their lower urinary tract symptoms,” says Kevin T. McVary, MD, FACS.
Disparities in ED diagnosis and referral across clinics who serve varying demographics
October 5th 2021To examine the disparities of ED diagnosis and referral, Denise Asafu-Adjei, MD, MPH, and a team of investigators conducted a study involving 2 outpatient urology settings who serve communities with varying demographics.